
- 239 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology. However, it has limitations in the assessment of certain tumours, above all (but not only) prostate cancer. Therefore, several non-FDG PET radiopharmaceuticals have been introduced into the clinical arena over the last few years, and this trend will continue to spread. The use of PET/CT with different PET radiopharmaceuticals that tailor to the type of tumour and biologic process that needs to be assessed is part of personalized precision medicine. The objective of this publication is to provide a case-based way of understanding normal biodistribution, variants, and pitfalls, including several examples of typical patterns for the main indications for each of the new non-FDG PET radiopharmaceuticals. This should facilitate the interpretation of images to support accurate diagnosis. This Atlas will allow professionals interested in non-FDG PET/CT imaging to embrace the variety of oncological imaging by providing clinically relevant teaching files on the effectiveness and diagnostic quality of non-FDG-PET/CT imaging in routine applications.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- 1. INTRODUCTION
- 3. Bevacizumab (89Zr)
- 4. Choline (11C)
- 5. Choline (18F)
- 6. FLUORO-DIHYDROTESTOSTERONE — FDHT (18F)
- 7. F-DOPA (18F)
- 8. Fluoroestradiol, FES (18F)
- 9. Fluoroethyl-tyrosine, FET (18F)
- 10. FLUOROTHYMIDINE, FLT (18F)
- 11. FLUCICLOVINE, FACBC (18F)
- 12. FMISO (18F)
- 13. FAZA (18F)
- 14. EXENDIN (68Ga)
- 15. 5-HYDROXYTRYPTOPHAN, HTP (11C)
- 16. METHIONINE (11C)
- 17. SODIUM FLUORIDE, NaF (18F)
- 18. SODIUM IODIDE, NaI (124I)
- 19. PSMA LIGAND (68Ga)
- 20. SOMATOSTATIN ANALOGUES (68Ga)
- 21. TRASTUZUMAB (89Zr)
- 22. YTTRIUM MICROSPHERES AFTER SELECTIVE INTERNAL RADIATION THERAPY (90Y)
- ABBREVIATIONS
- REFERENCES
- LIST OF CONTRIBUTORS TO DRAFTING AND REVIEW